Skip to main content
. 2016 Jun 24;7(31):49268–49280. doi: 10.18632/oncotarget.10284

Figure 6. AR promotes DNAH8 transcription in prostate cancer cells.

Figure 6

(A) Meta-analysis from 1476 prostate cancer cases shown a positive correlation between DNAH8 and PSA expression in prostate cancer (correlation coefficient 0.13, upper limit 0.18, lower limit 0.08, p < 0.05). (B) C4-2 cells were treated with vehicle or the indicated concentrations of DHT for 48 hours and western blot for DNAH8 and PSA was performed. (C) LNCaP and C4-2 cells in complete media were treated as above with vehicle, DHT, or the AR antagonist Casodex (10 μM). After 48 hr, cell RNA was harvested for q-RT-PCR to measure DNAH8 expression levels. (D) AR binds to the DNAH8 promoter. C4-2 cells in compete-media were treated with control or 10 nM DHT for 24 hr, and a ChIP assay for AR was performed. Primer pairs that span the −2000 to +400 region of the DNAH8 promoter were used to assess AR recruitment to the DNAH8 promoter. AR occupancy in the absence (white bars) and presence (black bars) of DHT treatment is shown. Values are normalized to input DNA. (E) Schematic showing DNAH8 regulates AR in prostate cancer after androgen deprivation.